BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1658919)

  • 1. Serum tumour markers in lung cancer.
    Hansen M
    Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum neurone-specific enolase and other neuroendocrine markers in lung cancer.
    Ledermann JA
    Eur J Cancer; 1994; 30A(5):574-6. PubMed ID: 8080666
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biological markers in lung cancer].
    Nikliński J; Furman M
    Pneumonol Alergol Pol; 1991; 59(5-6):253-9. PubMed ID: 1668877
    [No Abstract]   [Full Text] [Related]  

  • 4. Elastase levels in small and non-small cell lung carcinoma.
    Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer].
    Kushlinskiĭ NE; Liubimova NV; Lemeshko AO; Vasil'ev AV; Davydov MI
    Biull Eksp Biol Med; 1997 Jan; 123(1):98-100. PubMed ID: 9213472
    [No Abstract]   [Full Text] [Related]  

  • 6. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
    Wu Y; Wu Y; Wang L; Qu L
    Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study on the diagnosis and prognosis of lung cancer by using new simultaneously observed seromarkers.
    Zhang Q; Ren H; Wang B
    Ann N Y Acad Sci; 1995 Sep; 768():337-40. PubMed ID: 8526382
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of "neuron-specific enolase" as a tumor marker for small cell carcinoma of the lung.
    Güner G; Oktay G; Akkoçlu A; Karlikaya C
    Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):306S. PubMed ID: 8224452
    [No Abstract]   [Full Text] [Related]  

  • 9. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
    Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
    Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of neuron-specific enolase, carbohydrate antigen 19-9 and carbohydrate antigen 125 in carcinoma of the lung.
    Oktay G; Güner G; Karlikaya C; Akkoçlu A
    Biochem Soc Trans; 1995 May; 23(2):211S. PubMed ID: 7672232
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer.
    Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer.
    O'Shea P; Cassidy M; Freaney R; McCarthy P; Fennelly J
    Ir J Med Sci; 1995 Jan; 164(1):31-6. PubMed ID: 7890531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers and IL-2R in lung cancer.
    Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
    Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
    Muley T; Ebert W; Stieber P; Raith H; Holdenrieder S; Nagel D; Fürst H; Roth HJ; Luthe H; Blijenberg BG; Gurr E; Uhl W; von Pawel J; Drings P
    Clin Chem Lab Med; 2003 Jan; 41(1):95-103. PubMed ID: 12636057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic type definition in clinical trials on advanced non-small cell lung cancer.
    Rossi G; Cavazza A
    J Thorac Oncol; 2011 Feb; 6(2):405. PubMed ID: 21252724
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic and diagnostic usefulness of serum markers in lung cancer.
    Stahel RA; Martz G
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):893-4. PubMed ID: 2822425
    [No Abstract]   [Full Text] [Related]  

  • 18. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors.
    Paone G; De Angelis G; Portalone L; Greco S; Giosué S; Taglienti A; Bisetti A; Ameglio F
    Br J Cancer; 1997; 75(3):448-50. PubMed ID: 9020496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possible causes for an increased content of blood peptide hormones in small-cell lung cancer].
    Raĭkhlin NT; Smirnova EA; Blinova SA; Deĭneko GM; Bassalyk LS
    Vopr Onkol; 1989; 35(2):203-7. PubMed ID: 2564709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.